EdgarLookup

Hepion Pharmaceuticals, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Hepion Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q1 2024 Mar 31, 2024 $0 May 21, 2024
Q3 2023 Sep 30, 2023 $0 Nov 20, 2023
Q2 2023 Jun 30, 2023 $0 Aug 14, 2023
Q1 2024 Mar 31, 2023 $0 May 21, 2024
Q3 2023 Sep 30, 2022 $0 Nov 20, 2023
Q2 2023 Jun 30, 2022 $0 Aug 14, 2023
Q1 2023 Mar 31, 2022 $0 May 12, 2023
Q3 2022 Sep 30, 2021 $0 Nov 14, 2022
Q2 2022 Jun 30, 2021 $0 Aug 15, 2022
Q1 2022 Mar 31, 2021 $0 May 16, 2022
Q3 2021 Sep 30, 2020 $0 Nov 15, 2021
Q2 2021 Jun 30, 2020 $0 Aug 16, 2021
Q1 2021 Mar 31, 2020 $0 May 14, 2021

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($472.5K) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($1.04M) Aug 14, 2025
Q3 2025 Jun 30, 2025 ($1.04M) Nov 12, 2025
Q3 2025 Mar 31, 2025 ($6.11M) Nov 12, 2025
Q1 2025 Mar 31, 2025 ($6.11M) May 19, 2025
Q2 2025 Mar 31, 2025 ($6.11M) Aug 14, 2025
Q3 2025 Sep 30, 2024 ($4.87M) Nov 12, 2025
Q3 2025 Jun 30, 2024 ($3.93M) Nov 12, 2025
Q2 2025 Jun 30, 2024 ($3.93M) Aug 14, 2025
Q1 2025 Mar 31, 2024 ($2.85M) May 19, 2025
Q2 2025 Mar 31, 2024 ($2.85M) Aug 14, 2025
Q3 2025 Mar 31, 2024 ($2.85M) Nov 12, 2025
Q3 2024 Sep 30, 2023 ($10.53M) Nov 14, 2024
Q3 2024 Jun 30, 2023 ($14.08M) Nov 14, 2024
Q2 2024 Jun 30, 2023 ($14.08M) Aug 13, 2024
Q3 2024 Mar 31, 2023 ($13.26M) Nov 14, 2024
Q2 2024 Mar 31, 2023 ($13.26M) Aug 13, 2024
Q1 2024 Mar 31, 2023 ($13.26M) May 21, 2024
Q3 2023 Sep 30, 2022 ($8.55M) Nov 20, 2023
Q3 2023 Jun 30, 2022 ($19.91M) Nov 20, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($527.9K) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($1.75M) Aug 14, 2025
Q1 2025 Mar 31, 2025 ($1.28M) May 19, 2025
Q3 2025 Sep 30, 2024 ($4.46M) Nov 12, 2025
Q2 2025 Jun 30, 2024 ($8.50M) Aug 14, 2025
Q1 2025 Mar 31, 2024 ($5.18M) May 19, 2025
Q3 2024 Sep 30, 2023 ($10.66M) Nov 14, 2024
Q2 2024 Jun 30, 2023 ($14.17M) Aug 13, 2024
Q1 2024 Mar 31, 2023 ($13.21M) May 21, 2024
Q3 2023 Sep 30, 2022 ($8.47M) Nov 20, 2023
Q2 2023 Jun 30, 2022 ($20.00M) Aug 14, 2023
Q1 2023 Mar 31, 2022 ($7.25M) May 12, 2023
Q3 2022 Sep 30, 2021 ($8.52M) Nov 14, 2022
Q2 2022 Jun 30, 2021 ($6.85M) Aug 15, 2022
Q1 2022 Mar 31, 2021 ($6.03M) May 16, 2022
Q3 2021 Sep 30, 2020 ($6.23M) Nov 15, 2021
Q2 2021 Jun 30, 2020 ($4.78M) Aug 16, 2021
Q1 2021 Mar 31, 2020 ($4.19M) May 14, 2021
Q3 2020 Sep 30, 2019 ($1.91M) Nov 16, 2020
Q2 2020 Jun 30, 2019 ($1.70M) Aug 12, 2020